Clinical Trials Logo

Filter by:
NCT ID: NCT06019923 Recruiting - Ovarian Cancer Clinical Trials

Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

Start date: October 26, 2023
Phase:
Study type: Observational

Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels are below the detection limit. Therefore, there is a need to identify new prognostic biomarkers and monitor their dynamic changes for effective risk stratification and personalized treatment in patients with ovarian cancer

NCT ID: NCT06019702 Recruiting - Clinical trials for Digestive System Neoplasms

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms

Start date: September 8, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 alone in subjects with advanced digestive system neoplasms.

NCT ID: NCT06019468 Recruiting - Thymic Carcinoma Clinical Trials

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Start date: September 4, 2023
Phase: Phase 2
Study type: Interventional

The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.

NCT ID: NCT06019455 Recruiting - Lung Cancer Clinical Trials

The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.

Start date: June 1, 2022
Phase:
Study type: Observational

This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.

NCT ID: NCT06019273 Recruiting - HIV Infection Clinical Trials

Impacts of Different ART Regimens on Lipid Metabolism in People Living With HIV

ART
Start date: April 25, 2022
Phase:
Study type: Observational [Patient Registry]

To compare the dynamic changes of lipid metabolism of people living HIV who treated with different antiretroviral therapy (ART) regimens such as Biktarvy EVG/c/TAF/FTC, DTG/FTC/TDF, TDF/3TC/EFV, etc. And to assess the safety and efficacy of different antiretroviral therapy.

NCT ID: NCT06019013 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of QLF3108 in Participants With Advanced Solid Tumor

Start date: August 16, 2023
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of QLF3108 and will make a preliminary assessment of the anti-tumor activity of QLF3108 in patients with advanced solid tumor.

NCT ID: NCT06018935 Recruiting - Ovarian Cancer Clinical Trials

A Cohort Establishment Study of Total Management of Ovarian Cancer

Start date: June 17, 2024
Phase:
Study type: Observational

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

NCT ID: NCT06018896 Recruiting - Clinical trials for Metastatic Pancreatic Cancer

Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer

PTCA199-4
Start date: August 25, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of vitamin C in improving the quality of life for metastatic pancreatic cancer patients who are resistant to chemotherapy.

NCT ID: NCT06018883 Recruiting - Clinical trials for Metastatic Pancreatic Adenocarcinoma

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer

PTCA199-3
Start date: August 20, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of low-dose vitamin C on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.

NCT ID: NCT06018870 Recruiting - Glioma Clinical Trials

MRI Contrast Clearance Analysis for Glioma Grading and Genotyping

Start date: June 1, 2023
Phase:
Study type: Observational

Gliomas are the most common primary brain tumor. Gliomas with different grades have different clinical behaviors that determine treatment planning and patient prognosis in clinical practice. In the 2021 World Health Organization (WHO) classification of tumors for the central nervous system, glioma genotyping was considered the most relevant information for neuroradiologists. The isocitrate dehydrogenase (IDH) genotype and 1p/19q codeletion status are two essential molecular markers that divide glioma into three groups: IDH wild-type, IDH mutant with 1p/19q non-codeletion, and IDH mutant with 1p/19q codeletion. MRI contrast clearance analysis (CCA) is based on T1 delayed-contrast subtraction map, Blue/tumor regions in CCA represent efficient clearance of contrast from the tissue (delayed signal<early signal), while red/nontumor regions in CCA represent contrast accumulation (delayed signal>early signal). However, there are not any reports on the role of MRI CCA in glioma grading and genotyping, Thus, We hypothesized that the proportion of blue/red region and their histogram analyses, which could be acquired for predicting IDH genotypes and 1p/19q codeletion in gliomas, and to assess the application of CCA in glioma grading.